DOCSLIB.ORG

Mechanistic Classes of Antibacterials No Transitions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mechanistic Classes of Antibacterials No Transitions Mechanistic Classes of Antibacterials Benjamin D. Horning Group Meeting November 30, 2011 http://images.agoramedia.com/cs/eh/cs_diarrhea_antibiotics_causing_diarrhea_article.jpg http://www.irishhealth.com/content/image/853/Image1.jpg Walsh, C. T. Antibiotics: Actions, Origins, Resistance, American Society for Microbiology Press, Washington DC, 2003 Antibacterials- A Subclass of Antibiotics An antibiotic is “a chemical substance having the capacity, in dilute solution, to kill or inhibit growth of microorganisms.” This definition includes antifungals and antiprotozoals. Antibiotics travel inside the body to fight microorganisms, antiseptics are used externally, and disinfectants are for non-living surfaces. antimicrobials antibiotics disinfectants antiseptics antibacterials antifungals antiprotozoals applied to non- for external applications for internal or kill fungus kill protozoans living objects to living organisms external use (single-celled eukaryotes) http://www.lysol.com/images/products/no-mess-automatic-toiletbowl-cleaner.png, http://www.couponmamacentral.org/wp-content/uploads/2011/09/purell.jpg, http://www.medexpressrx.com/blog/wp-content/uploads/2010/07/antibiotics4.jpg, http://drugster.info/drug/medicament/22969/, http://modernmedicalguide.com/wp-content/uploads/2010/03/Antiprotozoal-Drugs.jpg Antibacterials- A Subclass of Antibiotics in vitro antibacterials human antibacterials veterinary and feedstock antibacterials S. pyogenes S. pneumoniae S. mutans Streptococcus pyogenes - strep throat, rheumatic fever, scarlet fever, necrotizing fasciitis Streptococcus pneumoniae - (bacterial) pneumonia Streptococcus agalactiae - meningitis, (bacterial) pneumonia Escherichia coli - gastroenteritis, urinary tract infections, sepsis, diarrhea (Methicillin-resistant) Staphylococcus aureus (MRSA) - Imepetigo, Staph infections, toxic shock syndrome Image from: http://inst.bact.wisc.edu/inst/images/book_3/chapter_13/13-3.jpg http://www.webcitation.org/5uJyti0mG http://www.medicinenet.com/sepsis/page4.htm Top-Selling Antibiotics in the USA O Me Me Me Me Me Me 21 54 N N 94 Me OH N F CO2H H H H H OH OH N N NH2 NH2 N O OH OH Me Me OH O OH O O OH O OH O O Levaquin (Levofloxacin) Solodyn (Minocycline) Doryx (Doxycycline) Ortho-McNeil Medicis Medicis $1,355 Million $673 Million $673 Million O O O 97 125 126 F CO2H F CO2H F CO2H H H N N N N N N HN HN OMe HN OMe H H Avelox (Moxifloxacin) Ciprodex otic Vigamox (Moxifloxacin) (Cipro and Dexamethasone) Merck Alcon $353 Million Alcon $255 Million $253 Million HO Me OH Me Me OH 138 O 160 H3N O 166 Me OH N HO O O H H O Cl OH O Me O O O N N H Cl OHMe Me HO O O O NH N Me H O H 2 N N F O H N N N OH N H O H H H NHMe H H OH O OH O O O HO O NH2 O Zyvox (Linezolid) HO OH Oracea (Doxycycline) OH Pfizer Vancocin (Vancomycin) ViroPharma Galderma $223 Million $192 Million $187 Million http://cbc.arizona.edu/njardarson/group/top-pharmaceuticals-poster Antibiotics- Why You Should Care of 57 million annual deaths Vaccinations and antibiotics can cure or prevent the majority of infectious diseases currently afflicting humanity. Antibiotic use introduces evolutionary selection pressure to bacteria; Resistant strains are selected for, and cause antibiotics to become ineffective. Bacterial resistance has been observed for every class of antibiotic introduced, sometimes within one year. New therapies will be needed. Graph from: Morens, D. M.; Folkers, G. K.; Fauci, A. S. Nature 2004, 430, 242-249 Table from: Palumbi, S. R. Science 2001, 293, 1786-1790 Strategies to Slow the Development of Antibiotic Resistance 108 bacteria 1 bacterium 108 bacteria antibiotic bacterial one error per 107 bases selection for completely resistant treatment growth 10 mutants (~0.3% of genes) resistant bacteria Overkill (multiple antibiotics) has worked well for HIV/AIDS, but not always applicable for bacteria (side effects). Direct observation therapy - continue antibiotic dose until no bacteria remain (not practical). Use narrow-spectrum antibiotics when applicable. Withhold the most powerful drugs - prevented vancomycin resistance for >30 years - difficult business model for pharma. Continue to develop new therapies and improve old therapies. Palumbi, S. R. Science 2001, 293, 1786-1790 Bacterial Resistance - Three Flavors Three types of bacterial resistance to antibiotics have been observed, coming either from random mutation under the selection pressure of antibiotics, or from antibiotic-producing NH2 bacteria. Resistance can be spread amongst bacteria via horizontal gene transfer. N N N N O H N O S Ph Me O N Me O OH O CO2H H2O RlmN Cfr !-lactamase Ph NH2 N N O NH Me N O S N Me Me O OH HN Me O CO2H O OH antibiotic modification export pumps enzymatic target (only natural products (efflux) modification and semisynthetics) http://www.sciencephoto.com/image/151999/530wm/C0089313-Active_efflux,_artwork-SPL.jpg Fujimori, D. G. et. al. J. Am. Chem. Soc. 2010, 132, 3953-3964 Paul Ehrlich and Drug Discovery Made seminial contributions in histology, haematology, immunology, oncology, microbiology and pharmacology. Alongside Ilya Mechnikov, won the Nobel Prize in Physiology or Medicine in 1908 “in recognition of their work on immunity.” Most famous for his discovery of Salvarsan (arsphenamine, #606), a compound for the treatment of syphilis, which was discovered during the first screen of a library of compounds for pharmaceutical activity, and later part of the first optimization of a lead, becoming the first blockbuster drug and presaging modern drug discovery. OH HO H2N HO H2N NH2 NH2 Paul Ehrlich and Sahachiro Hata H N As Frankfurt 1910 As 2 As As OH As OH As As As As As HO NH2 HO NH NH2 NH 2 2 Revised structure of Salvarsan OH HO NH2 OH Bosch, F.; Rosich, L. Pharmacology 2008, 82, 171-179 www.nobelprize.org/nobel_prizes/medicine/laureates/1908/ Salvarsan http://pubs.acs.org/cen/coverstory/83/8325/8325salvarsan.html Lloyd, N. C.; Morgan, H. W.; Nicholson, B. K.; Ronimus, R. S. Angew. Chem. Int. Ed. 2005, 44, 941-944 The Four Major Targets of Antibiotics Walsh, C. T. Nature Reviews Microbiology 2003, 1, 65-70 Walsh, C. T. Antibiotics: Actions, Origins, Resistance, American Society for Microbiology Press, Washington DC, 2003 The Four Major Targets of Antibiotics Antibiotics either target processes that are unique to bacteria - cell wall biosynthesis and folate metabolism - or processes that have different enough machinery to allow selective inhibition of bacterial over human versions - protein biosynthesis and DNA and RNA replication and repair. O O O H NH2 NH2 N Me S S S NH2 O O O O N H2N N H2N H N Sulfanilamide - 1936 2 Prontosil - 1932 Sulfacetamide O H N O CO2H S Me O N O O N H H H2N N HN N HO2C H Sulfamethoxazole H2N N N H Tetrahydrofolic acid NH2 OMe N H2N N OMe OMe Trimethoprim - 1940s Walsh, C. T. Nature Reviews Microbiology 2003, 1, 65-70 Walsh, C. T. Antibiotics: Actions, Origins, Resistance, American Society for Microbiology Press, Washington DC, 2003 Antibacterials Inhibiting Bacterial Folate Biosynthesis Prontosil was the first sulfa drug, discovered by O Gerhard Domagk while working for Bayer AG. NH2 S NH Bayer AG hoped to use its expertise in dyes to 2 O develop a Ehrlich-style “magic bullet” dye that could N N be selective for pathogenic bacteria, found Prontosil. Immensely successful as the first broad-spectrum H N 2 Prontosil - 1932 antibiotic. Bayer AG’s revenue stream was undercut when a team of French scientists found that Prontosil is a prodrug, and becomes sulfanilamide in the body, the patent for which had long ago expired. in vivo Gerhard Domagk metabolism Massive product and marketing of sulfanilamide Nobel Prize 1939 followed; One preparation, called Elixir “for the discovery Sulfanilamide, was a solution in ethylene glycol. of the antibacterial This raspberry-flavored concoction caused over effects of prontosil” O NH2 100 deaths in 1937. S O In 1938, the FDA passed the Federal Food, Drug H2N and Cosmetic Act, requiring safety tests for a variety of product. This is why we do clinical trials Sulfanilamide - 1936 for all new medicines today. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1939/domagk.html# http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SulfanilamideDisaster/default.htm for a history of clinical trials, see: http://blogs.scientificamerican.com/guest-blog/2011/10/06/molecules-to-medicine-clinical-trials-for-beginners/ Sulfa Drugs - Tetrahydrofolate Biosynthesis in Bacteria O O O O P P P P O O O OH O O O OH O- O- O- O- N N O H HN HN N CO2H S Me O N H2N N N para-amino H2N N N O H H H2N benzoate H2N 7,8-Dihydropteroate Synthase 7,8-Dihydropteroate Synthase O H N CO2H S O O Me O N O N N HN N HN N H H H2N N N H2N N N H H 7,8-Dihydropteroate 7,8-Dihydropteroate O CO2H O CO2H O N O N H NADPH H H N N HN N HO2C HN N HO2C H H H2N N N H2N N N H H 7,8-Dihydrofolate 5,6,7,8-Tetrahydrofolate Sulfa Drugs - Tetrahydrofolate Biosynthesis in Bacteria O O O O O H P P N P P O O O OH S O O O OH O- O- Me O- O- N O N N O H HN HN O N CO2H S H2N Me O N H2N N N para-amino SulfamethoxazoleH2N N N O H H H2N benzoate H2N combination 7,8-Dihydropteroate Synthase marketed as 7,8-Dihydropteroate Synthase co-trimoxazole O H N CO2H NH2 S O O Me OMe George H.O Hitchings N O N N N Nobel Prize 1988 HN N HN N H H “for their discoveries of H2N N OMe important principles for H2N N N H2N N N H OMe H drug treatment” 7,8-Dihydropteroate Trimethoprim 7,8-Dihydropteroate O CO2H O CO2H O N O N H NADPH H H N N HN N HO2C HN N HO2C H H H2N N N H2N N N H H 7,8-Dihydrofolate 5,6,7,8-Tetrahydrofolate Success and Failure with Bacterial Metabolite Biosynthesis OH O O Me fatty acid biosynthesis O N H OH OH O CO2H O platensymicin Me O N H H N n HN N HO2C OH H n H2N N N O H Me n Folate is an essential nutrient for humans, they cannot synthesize it.
Load more

Recommended publications
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • 1057-1064, 1984 the Effect of Pipemidic Acid on The
    Microbiol. Immunol. Vol. 28 (9), 1057-1064, 1984 The Effect of Pipemidic Acid on the Growth of a Stable L-Form of •ôNH•ôStaphylococcus aureus•ôNS•ô Kunihiko YABU,*,1 Hiromi ToMizu,1 and Yayoi KANDA2 1 Department of Biology, Hokuriku University School of Pharmacy, Kanazawa-machi, Kanazawa, Ishikawa ,920-11, and 2Department of Microbiology, Teikyo University School of Medicine, Kaga 2-chome, Ilabashi-ku, Tokyo 173 (Accepted for publication, June 12, 1984) Bacterial L-forms usually display spherical forms in an osmotically protective medium and seem to lack the typical binary fission process of cellular division ob servedin most bacteria (7). Although various modes of replication, such as budding binary fission, and release of elementary bodies from large bodies have been observed by light and electron microscopy (2, 5, 16), little is known about the processes involved in replication of L-forms. In the course of an experiment designed to test the effect of DNA synthesis inhibitors on the growth of a stable L-form of •ôNH•ôStaphylococcus•ôNS•ôaureus which grows in liquid medium, it was found that pipemidic acid, a synthetic antibacterial agent structurally related to nalidixic acid (13), induced a marked morphological altera tionat growth inhibitory concentrations. This study was initiated in an attempt to clarify the mechanism of replication of stable L-forms by analyzing the mor phologicalalteration caused by pipemidic acid. The stable L-form used was isolated as follows. S. •ôNH•ôaureus•ôNS•ôFDA 209P was grown in 10ml of Brain Heart Infusion broth (Difco) at 37C. The culture grown at 5•~105 colony-forming units (CFU) per ml was washed with saline by filtration and suspended in saline containing 100ƒÊg of N-methyl-N'-nitro-N-nitrosoguanidine per nil.
    [Show full text]
  • A TWO-YEAR RETROSPECTIVE ANALYSIS of ADVERSE DRUG REACTIONS with 5PSQ-031 FLUOROQUINOLONE and QUINOLONE ANTIBIOTICS 24Th Congress Of
    A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH 5PSQ-031 FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS 24th Congress of V. Borsi1, M. Del Lungo2, L. Giovannetti1, M.G. Lai1, M. Parrilli1 1 Azienda USL Toscana Centro, Pharmacovigilance Centre, Florence, Italy 2 Dept. of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), 27-29 March 2019 Section of Pharmacology and Toxicology , University of Florence, Italy BACKGROUND PURPOSE On 9 February 2017, the Pharmacovigilance Risk Assessment Committee (PRAC) initiated a review1 of disabling To review the adverse drugs and potentially long-lasting side effects reported with systemic and inhaled quinolone and fluoroquinolone reactions (ADRs) of antibiotics at the request of the German medicines authority (BfArM) following reports of long-lasting side effects systemic and inhaled in the national safety database and the published literature. fluoroquinolone and quinolone antibiotics that MATERIAL AND METHODS involved peripheral and central nervous system, Retrospective analysis of ADRs reported in our APVD involving ciprofloxacin, flumequine, levofloxacin, tendons, muscles and joints lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, cinoxacin, nalidixic acid, reported from our pipemidic given systemically (by mouth or injection). The period considered is September 2016 to September Pharmacovigilance 2018. Department (PVD). RESULTS 22 ADRs were reported in our PVD involving fluoroquinolone and quinolone antibiotics in the period considered and that affected peripheral or central nervous system, tendons, muscles and joints. The mean patient age was 67,3 years (range: 17-92 years). 63,7% of the ADRs reported were serious, of which 22,7% caused hospitalization and 4,5% caused persistent/severe disability. 81,8% of the ADRs were reported by a healthcare professional (physician, pharmacist or other) and 18,2% by patient or a non-healthcare professional.
    [Show full text]
  • CHM 114: Bioorganic Molecules Week 6 Laboratory
    CHM 114: Bioorganic Molecules Week 6 Laboratory Azosulfonamides: Part 1. Synthesis of a Ligand for Protein Binding Studies1 Dyes and Serendipity: In the Persian fairy tale The Three Princes of Serendip, the title characters were forever discovering things they were not looking for at the time—thus, serendipity is the aptitude for for making happy discoveries by accident. The preparation of the first commercially important synthetic dye by William Henry Perkin (not of Perkin’s restaurant fame) in 1854 is a good example of a serendipitous discovery in science. During the nineteenth century quinine was the only drug known to be effective against malaria, and it could be obtained only from the bark of the cinchona tree, which grew in South America. French chemists had isolated pure quinine from cinchona bark in 1820, but the inaccessibility of the tree made natural quinine very expensive. Perkin, then an 18-year-old graduate student working for the eminent German chemist August Wilhelm von Hofmann, realized that anyone who could make synthetic quinine might well become rich and famous. Perkin knew nothing about the molecular structure of quinine—structural organic chemistry was in its infancy in the mid-1800’s—but he knew that quinine’s molecular formula was C20H24N2O2. Perkin prepared some allytoluidine (C10H13N), apparently thinking that two molecules of allyltoluidine plus three oxygen atoms minus a molecule of water would magically yield C20H24N2O2 –quinine! (Figure 1). H H N N +3[O] 2 OH H H C -H2O 3 H3CO Allyltoluidine N Quinine Figure 1. Perkin’s Idea for the Synthesis of Quinine Of course Perkin had attempted the impossible.
    [Show full text]
  • A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sebastien Lefebvre
    A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sebastien Lefebvre To cite this version: Tessa Trouchon, Sebastien Lefebvre. A Review of Enrofloxacin for Veterinary Use. Open Journal of Veterinary Medicine, 2016, 6 (2), pp.40-58. 10.4236/ojvm.2016.62006. hal-01503397 HAL Id: hal-01503397 https://hal.archives-ouvertes.fr/hal-01503397 Submitted on 7 Apr 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NoDerivatives| 4.0 International License Open Journal of Veterinary Medicine, 2016, 6, 40-58 Published Online February 2016 in SciRes. http://www.scirp.org/journal/ojvm http://dx.doi.org/10.4236/ojvm.2016.62006 A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sébastien Lefebvre USC 1233 INRA-Vetagro Sup, Veterinary School of Lyon, Marcy l’Etoile, France Received 12 January 2016; accepted 21 February 2016; published 26 February 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract This review outlines the current knowledge on the use of enrofloxacin in veterinary medicine from biochemical mechanisms to the use in the field conditions and even resistance and ecotoxic- ity.
    [Show full text]
  • Antibiotic Resistance in the European Union Associated with Therapeutic Use of Veterinary Medicines
    The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/CVMP/342/99-Final Antibiotic Resistance in the European Union Associated with Therapeutic use of Veterinary Medicines Report and Qualitative Risk Assessment by the Committee for Veterinary Medicinal Products 14 July 1999 Public 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Switchboard: (+44-171) 418 8400 Fax: (+44-171) 418 8447 E_Mail: [email protected] http://www.eudra.org/emea.html ãEMEA 1999 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged TABLE OF CONTENTS Page 1. INTRODUCTION 1 1.1 DEFINITION OF ANTIBIOTICS 1 1.1.1 Natural antibiotics 1 1.1.2 Semi-synthetic antibiotics 1 1.1.3 Synthetic antibiotics 1 1.1.4 Mechanisms of Action 1 1.2 BACKGROUND AND HISTORY 3 1.2.1 Recent developments 3 1.2.2 Authorisation of Antibiotics in the EU 4 1.3 ANTIBIOTIC RESISTANCE 6 1.3.1 Microbiological resistance 6 1.3.2 Clinical resistance 6 1.3.3 Resistance distribution in bacterial populations 6 1.4 GENETICS OF RESISTANCE 7 1.4.1 Chromosomal resistance 8 1.4.2 Transferable resistance 8 1.4.2.1 Plasmids 8 1.4.2.2 Transposons 9 1.4.2.3 Integrons and gene cassettes 9 1.4.3 Mechanisms for inter-bacterial transfer of resistance 10 1.5 METHODS OF DETERMINATION OF RESISTANCE 11 1.5.1 Agar/Broth Dilution Methods 11 1.5.2 Interpretative criteria (breakpoints) 11 1.5.3 Agar Diffusion Method 11 1.5.4 Other Tests 12 1.5.5 Molecular techniques 12 1.6 MULTIPLE-DRUG RESISTANCE
    [Show full text]
  • Photodegradation Assessment of Ciprofloxacin, Moxifloxacin
    Hubicka et al. Chemistry Central Journal 2013, 7:133 http://journal.chemistrycentral.com/content/7/1/133 RESEARCH ARTICLE Open Access Photodegradation assessment of ciprofloxacin, moxifloxacin, norfloxacin and ofloxacin in the presence of excipients from tablets by UPLC-MS/MS and DSC Urszula Hubicka1*, PawełŻmudzki2, Przemysław Talik1, Barbara Żuromska-Witek1 and Jan Krzek1 Abstract Background: Ciprofloxacin (CIP), moxifloxacin (MOX), norfloxacin (NOR) and ofloxacin (OFL), are the antibacterial synthetic drugs, belonging to the fluoroquinolones group. Fluoroquinolones are compounds susceptible to photodegradation process, which may lead to reduction of their antibacterial activity and to induce phototoxicity as a side effect. This paper describes a simple, sensitive UPLC-MS/MS method for the determination of CIP, MOX, NOR and OFL in the presence of photodegradation products. Results: Chromatographic separations were carried out using the Acquity UPLC BEH C18 column; (2.1 × 100 mm, 1.7 μm particle size). The column was maintained at 40°C, and the following gradient was used: 0 min, 95% of eluent A and 5% of eluent B; 10 min, 0% of eluent A and 100% of eluent B, at a flow rate of 0.3 mL min-1. Eluent A: 0.1% (v/v) formic acid in water; eluent B: 0.1% (v/v) formic acid in acetonitrile. The method was validated and all the validation parameters were in the ranges acceptable by the guidelines for analytical method validation. The photodegradation of examined fluoroquinolones in solid phase in the presence of excipients followed kinetic of the first order reaction and depended upon the type of analyzed drugs and coexisting substances.
    [Show full text]
  • Belgian Veterinary Surveillance of Antibacterial Consumption
    Belgian Veterinary Surveillance of Antibacterial Consumption National consumption report 2013 1 Summary This fifth BelVetSAC report, covers the results of the data collection on veterinary antibacterial consumption in Belgium in the year 2013. Data consist of all veterinary antibacterials sold to a veterinarian or pharmacist in Belgium and of antibacterial premixes incorporated in medicated feed intended to be used in Belgium for the year 2013. It includes thus consumption data for farm animals as well as companion animals. The denominator for animal production was the biomass (in kg) calculated as the sum of the amount of beef, pork and poultry meat produced in 2013, plus the number of dairy cattle present in Belgium times 500 kg of metabolic weight per head. As the usage data are concerned, this report shows for the second year in a row a decrease in the total consumption of antibacterial compounds in veterinary medicine of -6,6% between 2012 and 2013. Due to the relative stable animal production (expressed in biomass -0,3%) the decrease expressed in mg/kg biomass is -6,3%. When using 2011 as a reference, a reduction of -12,7% (expressed in mg/kg biomass) was achieved between 2011 and 2013, distributed over a reduction of -13,3% in antibacterial pharmaceuticals and -10,2% in antibacterial premixes. When looking more in detail to the different types of antibacterials used, it is observed that the penicillines (31,1%), sulphonamides (28,7%), and tetracyclines (24,1%) remain the three most used antibacterial classes. This year a substantial decrease in sulphonamide plus trimethoprim use and a limited decrease in penicillin and tetracycline use was observed.
    [Show full text]
  • Fluoroquinolone Antibiotics: Ciprofloxacin, Levofloxacin, Moxifloxacin, Ofloxacin
    21 March 2019 DDL_fluoroquinolones_March-2019 Fluoroquinolone antibiotics: ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin New restrictions and precautions due to very rare reports of disabling and potentially long-lasting or irreversible side effects • Disabling, long-lasting or potentially irreversible adverse reactions affecting musculoskeletal (including tendonitis and tendon rupture) and nervous systems have been reported with fluoroquinolone antibiotics – see Drug Safety Update for more information • Prescribers and dispensers of fluoroquinolones should advise patients to stop treatment at the first signs of a serious adverse reaction, such as tendinitis or tendon rupture, muscle pain, muscle weakness, joint pain, joint swelling, peripheral neuropathy, and central nervous system effects, and to contact their doctor immediately for further advice – see MHRA sheet to discuss measures with patients • Fluoroquinolone treatment should be discontinued at the first sign of tendon pain or inflammation in patients and the affected limb or limbs appropriately treated (for example with immobilisation) Fluoroquinolones should not be prescribed for: • non-severe or self-limiting infections, or non-bacterial conditions • mild to moderate infections (such as in acute exacerbation of chronic bronchitis and chronic obstructive pulmonary disease) unless other antibiotics that are commonly recommended for these infections are considered inappropriate* • uncomplicated cystitis (for which ciprofloxacin or levofloxacin were previously authorised)
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Resistance Pattern of Coagulase Positive Staphylococcus Aureus Clinical Isolates from Asir Region, Kingdom of Saudi Arabia
    Journal of Microbiology and Antimicrobials Vol. 3(4), pp. 102-108, April 2011 Available online http://www.academicjournals.org/JMA ISSN 2141-2308 ©2011 Academic Journals Full Length Research Paper Resistance pattern of coagulase positive Staphylococcus aureus clinical isolates from Asir region, Kingdom of Saudi Arabia Mohamed E. Hamid Department of Microbiology, College of Medicine, King Khalid University, P. O. Box 641, Abha, Kingdom of Saudi Arabia. E-mail: [email protected]. Accepted 6 April, 2011 The objectives of this study were to determine the prevalence of methicillin resistant coagulase positive Staphlococcus aureus (MRSA) infections in two major hospitals in Asir region, Kingdom of Saudi Arabia and to compare it with the community-acquired infections. Two hundreds and ten coagulase positive S. aureus recovered from 9831 specimens from various infections at Asir Central Hospital and Abha General Hospital, KSA (Kingdom of Saudi Arabia), were tested against 44 commonly used antibacterial agents. One hundred of the isolates were from hospital-acquired infections, 100 from community-acquired infections and 10 isolates were collected from the hospital environment. All isolates were found resistant to aztreonam, colistin, mecillinam, metronidazole, polymyxin B and nalidixic acid but were sensitive to vancomycin, nitrofurantoin and novobiocin. Various levels of resistant were recorded for the remaining antibiotics. High resistance to antimicrobial agents was detected among hospital acquired infections compared to community acquired infections (p<0.01). The resistance rates of S. aureus to antimicrobial agents among hospital acquired infections isolates were significantly higher (p<0.05) than community acquired infections. This implies that hospital environment is a strong risk factor for the prevalence of MRSA in the hospitalized patients, visitors, and hospital staff with potential risk of spreading to the community.
    [Show full text]
  • Fluoroquinolone Mechanisms of Action and Resistance
    Downloaded from http://perspectivesinmedicine.cshlp.org/ on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance David C. Hooper1 and George A. Jacoby2 1Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts 02114 2Lahey Hospital and Medical Center, Burlington, Massachusetts 01805 Correspondence: [email protected] Quinolone antimicrobials are widely used in clinical medicine and are the only current class of agents that directly inhibit bacterial DNA synthesis. Quinolones dually target DNA gyrase and topoisomerase IV binding to specific domains and conformations so as to block DNA strand passage catalysis and stabilize DNA–enzyme complexes that block the DNA repli- cation apparatus and generate double breaks in DNA that underlie their bactericidal activity. Resistance has emerged with clinical use of these agents and is common in some bacterial pathogens. Mechanisms of resistance include mutational alterations in drug target affinity and efflux pump expression and acquisition of resistance-conferring genes. Resistance mu- tations in one or both of the two drug target enzymes are commonly in a localized domain of the GyrA and ParC subunits of gyrase and topoisomerase IV, respectively, and reduce drug binding to the enzyme–DNA complex. Other resistance mutations occur in regulatory genes that control the expression of native efflux pumps localized in the bacterial membrane(s). These pumps have broad substrate profiles that include other antimicrobials as well as quin- olones. Mutations of both types can accumulate with selection pressure and produce highly resistant strains. Resistance genes acquired on plasmids confer low-level resistance that promotes the selection of mutational high-level resistance.
    [Show full text]